These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23070190)

  • 21. Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).
    Tieu PT; Bach G; Matynia A; Hwang M; Neufeld EF
    Hum Mutat; 1995; 6(1):55-9. PubMed ID: 7550232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
    Thomas JA; Jacobs S; Kierstein J; Van Hove J
    J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucopolysaccharidosis Type I.
    Kubaski F; de Oliveira Poswar F; Michelin-Tirelli K; Matte UDS; Horovitz DD; Barth AL; Baldo G; Vairo F; Giugliani R
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32188113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
    Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparent allelism of the Hurler, Scheie, and Hurler/Scheie syndromes.
    Mueller OT; Shows TB; Opitz JM
    Am J Med Genet; 1984 Jul; 18(3):547-56. PubMed ID: 6433708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
    Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
    Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arthropathy-like findings and a carpal tunnel syndrome as the presenting features of Scheie syndrome: Three cases from the same family.
    Gökay S; Kardaş F; Kendirci M; Sözeri B
    Turk J Pediatr; 2018; 60(3):344-347. PubMed ID: 30511553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
    Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
    Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Hurler and Sanfilippo syndrome in a sibling pair.
    Sun A; Hopwood JJ; Thompson J; Cederbaum SD
    Mol Genet Metab; 2011 Jun; 103(2):135-7. PubMed ID: 21393040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation c.1190-1delG/N in intron 8 and c.1708G>C/N in exon 12 not reported in the IDUA gene developed a clinical phenotype of Scheie syndrome.
    Delgado Luengo WN; Miranda Contreras LE; Chávez CJ; Solis-Añez E; Cammarata-Scalisi F
    Invest Clin; 2014 Dec; 55(4):365-70. PubMed ID: 25558755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laronidase treatment of mucopolysaccharidosis I.
    Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
    BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sudden vision loss in a mucopolysaccharidosis I patient receiving enzyme replacement therapy.
    Yosunkaya E; Karaca E; Yilmaz SB; Gezdirici A; Guven G; Seven M; Yuksel A
    Genet Couns; 2011; 22(4):371-6. PubMed ID: 22303797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
    Gabrielli O; Clarke LA; Bruni S; Coppa GV
    Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler.
    Ferrara G; Maximova N; Zennaro F; Gregori M; Tamaro P
    Pediatr Transplant; 2014 May; 18(3):E96-9. PubMed ID: 24483599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.
    Pastores GM; Arn P; Beck M; Clarke JT; Guffon N; Kaplan P; Muenzer J; Norato DY; Shapiro E; Thomas J; Viskochil D; Wraith JE
    Mol Genet Metab; 2007 May; 91(1):37-47. PubMed ID: 17336562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations.
    Beesley CE; Meaney CA; Greenland G; Adams V; Vellodi A; Young EP; Winchester BG
    Hum Genet; 2001 Nov; 109(5):503-11. PubMed ID: 11735025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucopolysaccharidosis type I and craniosynostosis.
    Ziyadeh J; Le Merrer M; Robert M; Arnaud E; Valayannopoulos V; Di Rocco F
    Acta Neurochir (Wien); 2013 Oct; 155(10):1973-6. PubMed ID: 23917744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype.
    Scott HS; Litjens T; Hopwood JJ; Morris CP
    Hum Mutat; 1992; 1(2):103-8. PubMed ID: 1301196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
    Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
    J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.